Lifevantage Corp
For the period ended Jun 30, 2025. Filed Sep 4, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Sep 4, 2025
LFVN$4.56-13.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
The following documents are being filed as part of this report:
Financial Statements
(a)(1) Financial Statements. The following consolidated financial statements of LifeVantage Corporation and Report of Independent Registered Public Accounting Firm are included in a separate section of this Annual Report on Form 10-K.
(a)(2) All schedules for which provision is made in the applicable accounting regulations of the SEC are not required under the related instructions or are inapplicable, or because the required information is included in the financial statements or notes thereto, and therefore have been omitted.
Exhibits
(a)(3) The following exhibits are filed as part of, or incorporated by reference into, the Annual Report on Form 10-K.
| ExhibitNo. | Document Description | Filed Herewith or Incorporated by Reference From |
| 3.1 | Certificate of Incorporation | Exhibit 3.1 to Form 8-K filed with the SEC on March 13, 2018. |
| 3.2 | Amended and Restated Bylaws | Exhibit 3.1 to Form 8-K filed with the SEC on August 15, 2019. |
| 3.3 | Certificate of Designation of Series A Junior Participating Preferred Stock of the Company | Exhibit 3.1 to Form 8-K filed with the SEC on August 31, 2023. |
| 3.4 | Certificate of Elimination of Series A Junior Participating Preferred Stock of Registrant, filed November 18, 2024 | Exhibit 3.1 to Form 8-K filed with the SEC on November 19, 2024. |
| 4.1 | Form of Common Stock Certificate | Exhibit 4.1 to Form 8-K filed with the SEC on March 13, 2018. |
| 4.3 | Rights Agreement, dated as of August 30, 2023, by and between the Company and Computershare Trust Company, N.A., as Rights Agent | Exhibit 4.1 to Form 8-K filed with the SEC on August 31, 2023 |
| 10.1 | Cooperation Agreement, dated February 14, 2024, by and among the Company, the entities and persons listed on Exhibit A thereto, and the entities and persons listed on Exhibit B thereto | Exhibit 10.1 to Form 8-K filed with the SEC on February 15, 2024. |
| 10.2.1# | LifeVantage Corporation 2017 Long-Term Incentive Plan, as amended | Annex A to the Registrant’s Proxy Statement on Schedule 14A, filed with the SEC on September 20, 2024. |
| 10.2.2# | LifeVantage Corporation 2019 Employee Stock Purchase Plan, as amended | Annex B to the Registrant’s Proxy Statement on Schedule 14A, filed with the SEC on September 20, 2024. |
| 10.2.3# | Evolve Compensation Plan (United States), as amended on November 1, 2024 | Exhibit 10.3 to Form 10-Q filed for the fiscal quarter ended December 31, 2024 filed with the SEC on February 5, 2025. |
| ExhibitNo. | Document Description | Filed Herewith or Incorporated by Reference From |
| 10.2.4# | Evolve Compensation Plan (Australia), as amended on November 1, 2024 | Exhibit 10.4 to Form 10-Q filed for the fiscal quarter ended December 31, 2024 filed with the SEC on February 5, 2025. |
| 10.2.5# | Evolve Compensation Plan (New Zealand), as amended on November 1, 2024 | Exhibit 10.5 to Form 10-Q filed for the fiscal quarter ended December 31, 2024 filed with the SEC on February 5, 2025. |
| 10.2.6# | Evolve Compensation Plan (Japan), as amended on November 1, 2024 | Exhibit 10.6 to Form 10-Q filed for the fiscal quarter ended December 31, 2024 filed with the SEC on February 5, 2025. |
| 10.2.7# | Evolve Compensation Plan (Canada), as amended on November 1, 2024 | Exhibit 10.7 to Form 10-Q filed for the fiscal quarter ended December 31, 2024 filed with the SEC on February 5, 2025. |
| 10.2.8# | Evolve Compensation Plan (Mexico), as amended on November 1, 2024 | Exhibit 10.8 to Form 10-Q filed for the fiscal quarter ended December 31, 2024 filed with the SEC on February 5, 2025. |
| 10.2.9# | Evolve Compensation Plan (UK), as amended on November 1, 2024 | Exhibit 10.9 to Form 10-Q filed for the fiscal quarter ended December 31, 2024 filed with the SEC on February 5, 2025. |
| 10.2.10# | Evolve Compensation Plan (EU), as amended on November 1, 2024 | Exhibit 10.10 to Form 10-Q filed for the fiscal quarter ended December 31, 2024 filed with the SEC on February 5, 2025. |
| 10.2.11# | Evolve Compensation Plan (Philippines) | Exhibit 10.11 to Form 10-Q filed for the fiscal quarter ended March 31, 2025 filed with the SEC on May 6, 2025. |
| 10.2.12# | Evolve Compensation Plan (Taiwan) | Exhibit 10.11 to Form 10-Q filed for the fiscal quarter ended March 31, 2025 filed with the SEC on May 6, 2025. |
| 10.2.13# | Evolve Compensation Plan (Hong Kong) | Exhibit 10.11 to Form 10-Q filed for the fiscal quarter ended March 31, 2025 filed with the SEC on May 6, 2025. |
| 10.2.14# | Evolve Compensation Plan (Singapore) | Exhibit 10.11 to Form 10-Q filed for the fiscal quarter ended March 31, 2025 filed with the SEC on May 6, 2025. |
| 10.3# | Form of Restricted Stock Grant Agreement for the 2017 Long-Term Incentive Plan | Exhibit 99.2 to the Registration Statement on Form S-8 filed with the SEC on March 27, 2017. |
| 10.4# | Form of Stock Unit Agreement for the 2017 Long-Term Incentive Plan | Exhibit 99.3 to the Registration Statement on Form S-8 filed with the SEC on March 27, 2017. |
| 10.5# | LifeVantage Corporation 2019 Employee Stock Purchase Plan, as amended | Annex B to the Registrant’s Proxy Statement on Schedule 14A, filed with the SEC on September 20, 2024. |
| 10.6 | Form of Indemnification Agreement | Exhibit to 99.1 to Form 8-K filed with the SEC on March 13, 2018. |
| 10.7# | CEO Offer Letter, dated January 31, 2021, by and between the Company and Steven R. Fife | Exhibit 10.1 to Form 10-Q filed for the fiscal quarter ended March 31, 2021 filed with the SEC on April 29, 2021. |
| ExhibitNo. | Document Description | Filed Herewith or Incorporated by Reference From |
| 10.8# | Form of Key Executive Benefits Agreement | Exhibit 10.09# to Form 10-K for the fiscal year ended June 30, 2024 filed with the SEC on August 28, 2024. |
| 10.9 | Loan Agreement, dated April 12, 2024, by and between the Company and Bank of America, N.A. | Exhibit 10.1 to Form 8-K filed with the SEC on April 16, 2024. |
| 10.1 | Continuing and Unconditional Guaranty, dated April 12, 2024, by and among the Company, as Borrower, Lifeline Nutraceuticals Corporation, as Guarantor, and Bank of America, N.A. | Exhibit 10.2 to Form 8-K filed with the SEC on April 16, 2024. |
| 10.11 | Security and Pledge Agreement, dated April 12, 2024, by and among the Company, as Borrower, Lifeline Nutraceuticals Corporation, as Guarantor, and Bank of America, N.A. | Exhibit 10.3 to Form 8-K filed with the SEC on April 16, 2024. |
| 10.12 | Loan Agreement, dated March 30, 2016, by and between Z.B., N.A., the Company and Lifeline Nutraceuticals Corporation | Exhibit 10.1 to Form 8-K filed with the SEC on April 4, 2016. |
| 10.13 | Security Agreement, dated March 30, 2016, by and between Z.B., N.A., the Company and Lifeline Nutraceuticals Corporation | Exhibit 10.2 to Form 8-K filed with the SEC on April 4, 2016. |
| 10.14 | Amended No.1 to Loan Agreement, dated May 4, 2018, by and between Z.B., N.A., the Company and Lifeline Nutraceuticals Corporation | Exhibit 10.1 to Form 10-Q filed for the fiscal quarter ended March 31, 2018 filed with the SEC on May 9, 2018. |
| 10.15 | Second Loan Modification Agreement, dated February 1, 2019, by and between Zions Bank and the Company | Exhibit 10.1 to Form 8-K filed with the SEC on February 4, 2019. |
| 10.16 | Change in Terms Agreement, dated April 1, 2021, by and between Zions Bank and the Company | Exhibit 10.3 to Form 10-Q filed for the fiscal quarter ended March 31, 2021 filed with the SEC on April 29, 2021. |
| 10.17 | Change in Terms Agreement, dated September 30, 2022 by and between the Company and Zions Bank | Exhibit 10.1 to Form 10-Q filed for the fiscal quarter ended September 30, 2022 filed with the SEC on November 2, 2022. |
| 10.18 | Lease Agreement, dated November 14, 2019, by and between Traverse Ridge Center III and the Company | Exhibit 10.1 to Form 10-Q filed for the fiscal quarter ended December 31, 2019 with the SEC on January 28, 2020. |
| 10.19 | Lease Agreement, dated May 26, 2023, by and between Sumitomo Mitsui Trust Bank, Limited and LifeVantage Japan in US/English Format | Exhibit 10.1 to Form 10-Q filed for the fiscal quarter ended September 30, 2023 filed with the SEC on November 9, 2023. |
| 10.20* | Commercial Supply Agreement, dated January 31, 2014, by and between the Company and Deseret Laboratories, Inc. | Exhibit 10.1 to Form 10-Q for the fiscal quarter ended March 31, 2014 filed with the SEC on May 6, 2014. |
| 10.21* | Service Agreement, dated June 1, 2014, by and between IntegraCore, LLC and the Company | Exhibit 10.29 to Form 10-K for the fiscal year ended June 30, 2014 filed with the SEC on September 10, 2014. |
| 10.22* | Commercial Supply Agreement, dated May 30, 2014, by and between the Company and Wasatch Product Development | Exhibit 10.30 to Form 10-K for the fiscal year ended June 30, 2014 filed with the SEC on September 10, 2014. |
| 19.1 | Insider Trading Policy, amended and restated on April 29, 2025 | Filed herewith. |
| ExhibitNo. | Document Description | Filed Herewith or Incorporated by Reference From |
| 21.1 | List of Subsidiaries | Filed herewith. |
| 23.1 | Consent of Deloitte & Touche, LLP | Filed herewith. |
| 24.1 | Power of Attorney | Signature page to this report. |
| 31.1 | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | Filed herewith. |
| 31.2 | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | Filed herewith. |
| 32.1 | Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | Furnished herewith. |
| 32.2 | Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | Furnished herewith. |
| 97.1 | Company Policy for the Recovery of Erroneously Awarded Compensation (Clawback Policy) | Exhibit 97.1 to Form 10-K for the fiscal year ended June 30, 2024 filed with the SEC on August 28, 2024. |
| 101 | The following financial information from the registrant’s Annual Report on Form 10-K for the year ended June 30, 2025 formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations and Other Comprehensive Income; (iii) Consolidated Statement of Stockholders’ Deficit; (iv) Consolidated Statements of Cash Flows; and (v) Notes to Consolidated Financial Statements, tagged as blocks of text. | Filed herewith. |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | Filed herewith. |
| # | Management contract or compensatory plan. |
|---|---|
| * | The company has been granted confidential treatment for portions of this agreement. Accordingly, certain portions of this agreement have been omitted in the version filed with this report and such confidential portions have been filed with the SEC. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.